These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 30683238

  • 1. Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis.
    Di Tanna GL, Khaki AR, Theron G, McCarthy K, Cox H, Mupfumi L, Trajman A, Zijenah LS, Mason P, Bandason T, Durovni B, Bara W, Hoelscher M, Clowes P, Mangu C, Chanda D, Pym A, Mwaba P, Cobelens F, Nicol MP, Dheda K, Churchyard G, Fielding K, Metcalfe JZ.
    Lancet Glob Health; 2019 Feb; 7(2):e191-e199. PubMed ID: 30683238
    [Abstract] [Full Text] [Related]

  • 2. Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis.
    Haraka F, Kakolwa M, Schumacher SG, Nathavitharana RR, Denkinger CM, Gagneux S, Reither K, Ross A.
    Cochrane Database Syst Rev; 2021 May 06; 5(5):CD012972. PubMed ID: 34097769
    [Abstract] [Full Text] [Related]

  • 3. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial.
    Calligaro GL, Theron G, Khalfey H, Peter J, Meldau R, Matinyenya B, Davids M, Smith L, Pooran A, Lesosky M, Esmail A, Miller MG, Piercy J, Michell L, Dawson R, Raine RI, Joubert I, Dheda K.
    Lancet Respir Med; 2015 Aug 06; 3(8):621-30. PubMed ID: 26208996
    [Abstract] [Full Text] [Related]

  • 4. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N.
    Cochrane Database Syst Rev; 2014 Jan 21; 2014(1):CD009593. PubMed ID: 24448973
    [Abstract] [Full Text] [Related]

  • 5. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children.
    Kay AW, González Fernández L, Takwoingi Y, Eisenhut M, Detjen AK, Steingart KR, Mandalakas AM.
    Cochrane Database Syst Rev; 2020 Aug 27; 8(8):CD013359. PubMed ID: 32853411
    [Abstract] [Full Text] [Related]

  • 6. Rapid diagnosis of pulmonary tuberculosis in African children in a primary care setting by use of Xpert MTB/RIF on respiratory specimens: a prospective study.
    Zar HJ, Workman L, Isaacs W, Dheda K, Zemanay W, Nicol MP.
    Lancet Glob Health; 2013 Aug 27; 1(2):e97-e104. PubMed ID: 25104164
    [Abstract] [Full Text] [Related]

  • 7. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial.
    Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K, TB-NEAT team.
    Lancet; 2014 Feb 01; 383(9915):424-35. PubMed ID: 24176144
    [Abstract] [Full Text] [Related]

  • 8. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF.
    Churchyard GJ, Stevens WS, Mametja LD, McCarthy KM, Chihota V, Nicol MP, Erasmus LK, Ndjeka NO, Mvusi L, Vassall A, Sinanovic E, Cox HS, Dye C, Grant AD, Fielding KL.
    Lancet Glob Health; 2015 Aug 01; 3(8):e450-e457. PubMed ID: 26187490
    [Abstract] [Full Text] [Related]

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE, McCarthy K, Gous N, Nduna M, Van Rie A, Sanne I, Venter WF, Duse A, Stevens W.
    PLoS Med; 2011 Jul 01; 8(7):e1001061. PubMed ID: 21814495
    [Abstract] [Full Text] [Related]

  • 11. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study.
    Mishra H, Reeve BWP, Palmer Z, Caldwell J, Dolby T, Naidoo CC, Jackson JG, Schumacher SG, Denkinger CM, Diacon AH, van Helden PD, Marx FM, Warren RM, Theron G.
    Lancet Respir Med; 2020 Apr 01; 8(4):368-382. PubMed ID: 32066534
    [Abstract] [Full Text] [Related]

  • 12. Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial.
    Agizew T, Chihota V, Nyirenda S, Tedla Z, Auld AF, Mathebula U, Mathoma A, Boyd R, Date A, Pals SL, Lekone P, Finlay A.
    BMC Infect Dis; 2019 Dec 16; 19(1):1058. PubMed ID: 31842773
    [Abstract] [Full Text] [Related]

  • 13. Chest X-ray interpretation does not complement Xpert MTB/RIF in diagnosis of smear-negative pulmonary tuberculosis among TB-HIV co-infected adults in a resource-limited setting.
    Nakiyingi L, Bwanika JM, Ssengooba W, Mubiru F, Nakanjako D, Joloba ML, Mayanja-Kizza H, Manabe YC.
    BMC Infect Dis; 2021 Jan 13; 21(1):63. PubMed ID: 33435896
    [Abstract] [Full Text] [Related]

  • 14. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.
    Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M, Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA).
    Lancet Respir Med; 2013 Aug 13; 1(6):462-70. PubMed ID: 24429244
    [Abstract] [Full Text] [Related]

  • 15. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, Dendukuri N.
    Cochrane Database Syst Rev; 2013 Jan 31; (1):CD009593. PubMed ID: 23440842
    [Abstract] [Full Text] [Related]

  • 16. Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.
    Shapiro AE, Ross JM, Yao M, Schiller I, Kohli M, Dendukuri N, Steingart KR, Horne DJ.
    Cochrane Database Syst Rev; 2021 Mar 23; 3(3):CD013694. PubMed ID: 33755189
    [Abstract] [Full Text] [Related]

  • 17. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.
    Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens W, Scott L, Rodrigues C, Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango I, Murithi W, Dietze R, Lyrio Peres R, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner JJ, Denkinger CM, study team.
    Lancet Infect Dis; 2018 Jan 23; 18(1):76-84. PubMed ID: 29198911
    [Abstract] [Full Text] [Related]

  • 18. Use of the Xpert(®) MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia.
    Bates M, Ahmed Y, Chilukutu L, Tembo J, Cheelo B, Sinyangwe S, Kapata N, Maeurer M, O'Grady J, Mwaba P, Zumla A.
    Trop Med Int Health; 2013 Sep 23; 18(9):1134-1140. PubMed ID: 23834035
    [Abstract] [Full Text] [Related]

  • 19. Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa.
    Van Rie A, Page-Shipp L, Hanrahan CF, Schnippel K, Dansey H, Bassett J, Clouse K, Scott L, Stevens W, Sanne I.
    Int J Tuberc Lung Dis; 2013 Mar 23; 17(3):368-72. PubMed ID: 23407225
    [Abstract] [Full Text] [Related]

  • 20. Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study.
    Namugenyi J, Musaazi J, Katamba A, Kalyango J, Sendaula E, Kambugu A, Fehr J, Castelnouvo B, Manabe YC, Ssengooba W, Sekaggya-Wiltshire C.
    BMC Infect Dis; 2021 Jun 01; 21(1):513. PubMed ID: 34074248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.